Comparative Pharmacology
Head-to-head clinical analysis: INDOCIN SR versus RIMADYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDOCIN SR versus RIMADYL.
INDOCIN SR vs RIMADYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Indomethacin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing synthesis of prostaglandins, which mediate inflammation, pain, and fever. It also has a direct effect on renal blood flow and platelet aggregation.
Selective cyclooxygenase-2 (COX-2) inhibitor, reducing prostaglandin synthesis involved in inflammation, pain, and fever.
75 mg orally once daily, extended-release capsules.
50-100 mg orally twice daily, or 100-200 mg rectally once daily (suppository).
None Documented
None Documented
Terminal half-life is 4.5 hours (range 2.6-11.2 hours) in young adults; prolonged in elderly (up to 16 hours) and in patients with renal or hepatic impairment.
Terminal elimination half-life: 12–18 hours in dogs at recommended doses. Clinical context: Supports twice-daily dosing; longer half-life in some breeds may require dose adjustment.
Approximately 50% renal (as unchanged drug and metabolites, primarily glucuronide conjugates), 33% biliary/fecal. Indomethacin undergoes enterohepatic recirculation.
Primarily hepatic metabolism (oxidation, conjugation) with ~70% of metabolites excreted in urine and ~30% in feces via biliary elimination. Less than 5% excreted unchanged.
Category C
Category C
Nonsteroidal Anti-inflammatory Drug (NSAID)
Nonsteroidal Anti-inflammatory Drug (NSAID)